Endocrine treatment of advanced breast cancer

Acta Oncologica

Volumn 35, Issue SUPPL. 5, 1996, Pages 68-72

  Dowsett, Mitchell ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; LETROZOLE;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE CONGENERS; PROGESTINS;

EID: 0030483425     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609083973     Document Type: Article

References (32)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-107.
2. Early breast cancer trialists collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune-therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15 & 71-85.
3. Smith IE, Powles TJ. Chemotherapy: general principles. In: TJ Powles, IE Smith ed. Medical management of breast cancer. London: Martin Dunitz, 1991: 125-132.
4. Howell A, MacIntosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988; 24: 1567-1572.
5. McGuire WL, Carbone PP, Sears ME, Eschert GC. In: McGuire WL, Carbone PP, Vollmer EP, eds. Oestrogen receptors in human breast cancer. New York: Raven Press. 1975: 1-7.
6. Wittliff JL. Steroid hormone receptors in breast cancer. Cancer 1984; 53: 630-643.
7. Foekens JA, Portengen H, Look MP. Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Brit J Cancer 1994; 70: 1217-1223.
8. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1944; 343: 448-452.
9. Chander SK, Newton C, McCague R, Dowsett M, Luqmani Y, Coombes RC. Pyrrolodine-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antioestrogen tamoxifen for the treatment of breast cancer. Cancer Res 1991; 51: 5851-5858.
10. Johnston SRD, Haynes BP, Jarman N, Smith IE, Dowsett M. Reduced growth support by idoxifene in Tamoxifen-sensitive and resistant MCF7 breast cancer xenografts in athymic mice. Proc Am Assoc Cancer Res 1995; 36: 252.
11. DeFriend DJ, Howell A, Nicolson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54: 408-414.
12. Dowsett M, Howell R, Salter J, Thomas NM, Walton PLM, Thomas EJ Effects of the pure antioestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo. Human Reprod 1995; 10: 262-267.
13. Howell A, De Friend D, Robertson J, Blamey R, Morton P. Response to a specific anti-oestrogen (ICI-182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30.
14. Robertson JFR, Blamey RW, Howell A, Anderson L, De Friend D. Duration of response to ICI 182780 appears significantly longer than Megace in tamoxifen resistant breast cancer. Breast Cancer Res Treat 1996; 37(suppl): 33.
15. Santen RJ, Santner S, Davis B, Veldhuis J, Samojik S, Ruby E. Aminoglutethimide inhibits extra-glandular oestrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257-1265.
16. Stuart-Harris R, Smith IE, Dowsett M, et al. Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet 1984; 2: 604-607.
17. Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast cancinoma. Cancer Res (Suppl.) 1982; 42: 3430s-3433s.
18. Carrion RP, Candel VA, Calabresi F et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in post menopausal women with advanced breast cancer. Ann Oncology; 5(suppl. 7): 19-24.
19. Coombes RC, Hughes SWM, Dowsett M. 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer Eur J Cancer 1992; 28A: 1941-1945.
20. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993; 77: 324-331.
21. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet P, Dowsett M. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in postmenopausal patients with breast cancer. Cancer Res 1993; 53: 266-270.
22. Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ. The influence of intramuscular 4-hydroxyandrostenedioneon peripheral aromatisation in breast cancer patients. Eur. J. Cancer 1992; 28: 1712-1716.
23. MacNeill FA, Jones AL, Jacobs S, Lonning PE, Powles TJ, Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J. Cancer 1992; 66: 692-697.
24. Dowsett M, Jones A, Johnston, Jacobs S, Trunet P, Smith IE In vivo measurement of aromatase inhibition by letrozole in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511-1516.
25. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem 1992; 43: 155-159.
26. Dowsett M, Lal A, Smith IE and Jeffcoate SL. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. Br J Cancer 1987; 55: 311-313.
27. Birrell SN, Roder DN, Horsfall DJ, Bentel JN, Tithy DD. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol 1995; 13: 1572-1577.
28. Maudelonde T, Romieu G, Ulmann A, et al. First clinical trial on the use of antiprogesterone RU486 in advanced breast cancer. In: Klijn JGM, Paridaeras R, Foekens JA, eds. Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. New York: Raven Press, 1987; 55-59.
29. Lien EA, Anker G, Lonning PE, Solheim E, Ueland PN. Decreased serum concentrations of tamoxifen and its metabolites, induced by aminoglutethimide. Cancer Res 1990; 50: 5851-5857.
30. Dowsett M, Murray RML, Pitt P, Jeffcoate SL. Antagonism of aminoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients. Eur J Cancer Clin Oncol 1985; 21: 1063-1068.
31. Stein RC, Dowsett M, Hedley A, Coombes RC. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990; 62: 679-683.
32. Lonning PE, Dowsett M, Jones A, Ekse D, Jacobs S, MacNeill F, Johannessen DC, Powles TJ. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Res & Treatment 1992; 23: 57-62.